Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Change in Receivables (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Change in Receivables for 6 consecutive years, with $50000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 91.35% to $50000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2025, down 144.21% year-over-year, with the annual reading at -$1.1 million for FY2025, 144.21% down from the prior year.
  • Change in Receivables for Q4 2025 was $50000.0 at Lexicon Pharmaceuticals, down from $151000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $1.1 million in Q2 2024, with the low at -$1.0 million in Q1 2025.
  • Average Change in Receivables over 3 years is $196333.3, with a median of $254500.0 recorded in 2023.
  • The sharpest move saw Change in Receivables surged 174.93% in 2024, then crashed 298.84% in 2025.
  • Over 3 years, Change in Receivables stood at $692000.0 in 2023, then decreased by 16.47% to $578000.0 in 2024, then crashed by 91.35% to $50000.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $50000.0, $151000.0, and -$264000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.